<DOC>
	<DOCNO>NCT00250575</DOCNO>
	<brief_summary>Clozapine antipsychotic . This 24-week study evaluate safety efficacy clozapine patient treatment-resistant schizophrenia . This study recruit United States .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Clozapine Patients With Treatment-resistant Schizophrenia</brief_title>
	<detailed_description>Clozapine antipsychotic . This 24-week study evaluate safety efficacy clozapine patient treatment-resistant schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Diagnosed schizophrenia Not respond least two atypical antipshychotics launch Japan Inpatient Low white blood cell count Significant heart diseases Diabetes mellitus Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Schizophrenia , treatment-resistant , clozapine</keyword>
</DOC>